NCT03577275 - A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2018

Primary Completion Date

September 15, 2018

Study Completion Date

September 24, 2018

Conditions

Dyslipidemias

Interventions

DRUG

NST-4016 600mg

Likely maximum therapeutic dose of NST-4016

DRUG

Placebo oral capsule

Placebo for comparison with moxifloxacin and potential NST-4016 effects

DRUG

Moxifloxacin 400mg

Active comparator with known effect on QT interval

DRUG

NST-4016 2000mg

Supratherapeutic dose of NST-4016

Trial Locations (1)

Covance Clinical Research Unit (CRU) Ltd, Leeds